Generic Drug News and Research

RSS

Generic Drugs are official nonbrand names by which medicines are known. Generic names usually refer to the chemical name of the drug.

Ortho-McNeil settles patent cases against Par/Kali

Ortho-McNeil, Inc. has announced that it settled its patent litigation against Par Pharmaceutical Companies, Inc. and its subsidiaries, Par Pharmaceutical, Inc., and Kali Laboratories, Inc., generic drug manufacturers, regarding their infringement of the Ortho-McNeil patent for ULTRACET (tramadol/acetaminophen).

20 Jul 2007

Lupin receives approval for Amlodipine tablets

Lupin Pharmaceuticals, Inc. has announced that the U.S. Food and Drug Administration (FDA) has granted final approval for the Company's Abbreviated New Drug Application (ANDA) for Amlodipine Besylate Tablets, 2.5 mg (base), 5 mg (base) and 10 mg (base).

18 Jul 2007

Barr confirms Xopenex patent challenge

Barr Pharmaceuticals, Inc. has confirmed that its subsidiary, Barr Laboratories, Inc., has initiated a challenge of the patents listed by Sepracor Inc. in connection with its Xopenex (Levalbuterol Hydrochloride) 0.31mg/3mL, 0.63mg/3mL and 1.25mg/3mL.

17 Jul 2007

Barr confirms patent challenge of Aggrenox

Barr Pharmaceuticals, Inc. has confirmed that its subsidiary, Barr Laboratories, Inc., has initiated a challenge of the patent listed by Boehringer Ingelheim in connection with its Aggrenox Aspirin/Extended- Release Dipyridamole) 25 mg/200 mg capsules.

13 Jul 2007

Caraco Pharmaceutical Labs announces FDA approval to market generic Tenormin

Caraco Pharmaceutical Laboratories has announced that the US Food and Drug Administration (FDA) has granted final approval for the Company's Abbreviated New Drug Application (ANDA) for Atenolol Tablets USP (atenolol).

12 Jul 2007

Ranbaxy receives approval to manufacture and market Amlodipine Besylate tablets

Ranbaxy Pharmaceuticals Inc. (RPI), a wholly owned subsidiary of Ranbaxy Laboratories Limited (RLL), has announced that RLL has received final approval from the U.S. Food and Drug Administration to manufacture and market Amlodipine Besylate Tablets, 2.5 mg (base), 5 mg (base) and 10 mg (base).

11 Jul 2007

CMS issues final rule for Medicaid prescription drug reimbursements

CMS on Friday released a final rule that will change the Medicaid prescription drug reimbursement formula for pharmacies from being based on the average wholesale price to being based on the average manufacturer price, CongressDaily reports (Edney, CongressDaily, 7/10).

11 Jul 2007

Approval of generic Dostinex

Barr Pharmaceuticals, Inc. has announced that its subsidiary Barr Laboratories, Inc. has received final U.S. Food & Drug Administration (FDA) approval for its application to manufacture and market a generic version of Pharmacia and Upjohn Company's Dostinex (cabergoline) tablets, 0.5 mg.

10 Jul 2007

Actavis launches Terbinafine hydrochloride tablets in the U.S.

Actavis Group has announced that it has launched Terbinafine hydrochloride tablets in the U.S. Distribution of the product will commence immediately.

10 Jul 2007

Barr to market generic LAMISIL tablets

Barr Pharmaceuticals has announced that Gedeon Richter, Plc. has received final U.S. Food & Drug Administration (FDA) approval for its application to manufacture and market a generic version of Novartis Pharmaceutical Corporation's LAMISIL (terbinafine hydrochloride) Tablets, 250 mg. The approval follows the expiration of pediatric exclusivity for LAMISIL.

4 Jul 2007

Increase in prescription drug cost sharing associated with lower rates of drug treatment, adherence

A review of previous studies indicates that an increase in prescription drug cost sharing is associated with a decrease in drug spending and use of pharmacies; and for some chronic conditions, higher cost sharing is associated with greater use of expensive medical services, according to an article in the July 4 issue of JAMA: The Journal of the American Medical Association.

4 Jul 2007

Actavis launches Ondansetron tablets in the U.S.

Actavis Group has announced that it has launched Ondansetron Tablets in the U.S. Actavis will market the product under an agreement with Natco Pharma Limited. Distribution of the product will commence immediately.

28 Jun 2007

Print and phone programs help increase physical activity

As Americans struggle to become more physically active, simple programs that provide feedback and motivation can play a crucial role in getting people off to a good start, according to a study of the July issue of Health Psychology.

27 Jun 2007

Barr announces tentative approval for generic version of Effexor tablets

Barr Pharmaceuticals, Inc. has announced that its subsidiary PLIVA has received tentative approval from the U.S. Food and Drug Administration (FDA) for its generic version of Wyeth Pharmaceuticals Inc.'s Effexor (Venlafaxine Hydrochloride) Tablets, 25mg, 37.5mg, 50mg, 75mg and 100mg.

27 Jun 2007

Mylan receives FDA approval for Ondansetron tablets

Mylan Pharmaceuticals Inc. has received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Applications (ANDAs) for Ondansetron Hydrochloride (HCl) Tablets, 4 mg (base), 8 mg (base) and 24 mg (base), and Ondansetron Orally Disintegrating Tablets (ODT) USP, 4 mg and 8 mg.

26 Jun 2007

Scientists look at the ecosystem within us

For more than 100 years, scientists have known that humans carry a rich ecosystem within their intestines.

26 Jun 2007

Ranbaxy receives tentative FDA approval for Tamsulosin capsules

Ranbaxy Pharmaceuticals has announced that RLL has received tentative approval from the U.S. Food and Drug Administration to manufacture and market Tamsulosin Hydrochloride Capsules, 0.4 mg.

23 Jun 2007

Ranbaxy receives tentative approval to manufacture Amlodipine Besylate tablets

Ranbaxy Pharmaceuticals Inc. (RPI), a wholly owned subsidiary of Ranbaxy Laboratories Limited (RLL), announced that RLL has received tentative approval from the U.S. Food and Drug Administration to manufacture and market Amlodipine Besylate Tablets, 2.5 mg (base), 5 mg (base) and 10 mg (base).

23 Jun 2007

New trade agreement language to allow developing countries more flexibility in circumventing drug patents, other restrictions

Democratic lawmakers and U.S. trade officials are in the final stages of negotiation over language to be added to international free trade agreements that would allow developing countries more flexibility in circumventing drug patents and other restrictions on pharmaceuticals, sources said recently, CongressDaily reports.

22 Jun 2007

Medicare Part D plans vary across U.S.

An examination of Medicare Part D plans in California and Hawaii reveals wide variations in drug formularies, but indicates that for many classes of drugs, it is possible to find at least one or more drug that is covered by nearly all Part D plans, according to a study in the June 20 issue of JAMA: The Journal of the American Medical Association

20 Jun 2007